Immunocore Holdings plc (NASDAQ:IMCR) Given Average Recommendation of “Moderate Buy” by Brokerages

Immunocore Holdings plc (NASDAQ:IMCR) has been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $80.92.

A number of equities analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $81.00 price target on shares of Immunocore in a report on Thursday, April 11th. SVB Leerink assumed coverage on Immunocore in a report on Monday. They issued an “outperform” rating and a $74.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Immunocore in a report on Wednesday, March 6th. Canaccord Genuity Group upped their target price on Immunocore from $60.00 to $63.00 and gave the company a “hold” rating in a research report on Thursday, February 29th. Finally, Mizuho upped their target price on Immunocore from $86.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th.

Institutional Investors Weigh In On Immunocore

Institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its position in shares of Immunocore by 103.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock valued at $43,000 after acquiring an additional 426 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of Immunocore by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock valued at $181,000 after acquiring an additional 674 shares in the last quarter. JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of Immunocore during the 4th quarter valued at approximately $230,000. NEOS Investment Management LLC acquired a new stake in shares of Immunocore during the 4th quarter valued at approximately $262,000. Finally, Legato Capital Management LLC raised its position in shares of Immunocore by 61.7% during the 4th quarter. Legato Capital Management LLC now owns 7,235 shares of the company’s stock valued at $494,000 after acquiring an additional 2,762 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Stock Down 0.6 %

NASDAQ IMCR opened at $58.10 on Tuesday. The stock has a market cap of $2.89 billion, a PE ratio of -50.09 and a beta of 0.89. Immunocore has a fifty-two week low of $42.21 and a fifty-two week high of $76.98. The business has a 50 day moving average price of $62.10 and a two-hundred day moving average price of $60.89. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.12). The company had revenue of $70.16 million during the quarter, compared to analysts’ expectations of $53.25 million. Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The firm’s revenue was up 22.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.63) EPS. As a group, sell-side analysts predict that Immunocore will post -1.54 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.